ERBB3 and breast carcinoma: Collectively, our studies demonstrate that erbB3 receptor and IGF-1R differentially modulate lapatinib sensitivity in trastuzumab-resistant breast cancer cells; and specific knockdown of erbB3, but not IGF-1R, significantly promotes lapatinib-mediated growth inhibition and apoptosis.